These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8707747)

  • 41. Comparative in vitro susceptibility of a tetracycline-resistant Chlamydia trachomatis strain isolated in Toulouse (France).
    Lefèvre JC; Lépargneur JP
    Sex Transm Dis; 1998 Aug; 25(7):350-2. PubMed ID: 9713914
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis.
    Segreti J; Kessler HA; Kapell KS; Trenholme GM
    Antimicrob Agents Chemother; 1987 Jan; 31(1):100-1. PubMed ID: 2952061
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prediction of efficacy of antimicrobial agents in treatment of infections due to Chlamydia trachomatis.
    Bowie WR; Lee CK; Alexander ER
    J Infect Dis; 1978 Nov; 138(5):655-9. PubMed ID: 712119
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Comparative study of minimal inhibiting concentrations of doxycycline, ofloxacin and erythromycin against 18 recent isolates from Chlamydia trachomatis (1994-1995)].
    Bianchi A; Legouge R; Lefevre JC; Askienazy-Elbhar M; Joly-Guillou ML; Pavis A; Sednaoui P
    Pathol Biol (Paris); 1996 May; 44(5):347-50. PubMed ID: 8758473
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enzyme-linked immunosorbent assay for the in-vitro detection of sensitivity of Chlamydia trachomatis to antimicrobial drugs.
    Cevenini R; Donati M; Sambri V; Rumpianesi F; La Placa M
    J Antimicrob Chemother; 1987 Nov; 20(5):677-84. PubMed ID: 3323161
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The antimicrobial susceptibility of Chlamydia trachomatis in cell culture.
    Ridgway GL; Owen JM; Oriel JD
    Br J Vener Dis; 1978 Apr; 54(2):103-6. PubMed ID: 638716
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibiotic susceptibility of Chlamydia trachomatis.
    Blackman HJ; Yoneda C; Dawson CR; Schachter J
    Antimicrob Agents Chemother; 1977 Dec; 12(6):673-7. PubMed ID: 931365
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro assays of the efficacy of antimicrobial agents in controlling Chlamydia trachomatis propagation.
    Lee CK; Bowie WR; Alexander ER
    Antimicrob Agents Chemother; 1978 Mar; 13(3):441-5. PubMed ID: 162541
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Commercially available fluorescein-conjugated monoclonal antibody for determining the in vitro activity of antimicrobial agents against Chlamydia trachomatis.
    Webberley JM; Matthews RS; Andrews JM; Wise R
    Eur J Clin Microbiol; 1987 Oct; 6(5):587-9. PubMed ID: 2449348
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chlamydia trachomatis: in vitro susceptibility of genital and ocular isolates to some quinolones, amoxicillin and azithromycin.
    Børsum T; Dannevig L; Størvold G; Melby K
    Chemotherapy; 1990; 36(6):407-15. PubMed ID: 1963393
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Variation in the mutation frequency determining quinolone resistance in Chlamydia trachomatis serovars L2 and D.
    Rupp J; Solbach W; Gieffers J
    J Antimicrob Chemother; 2008 Jan; 61(1):91-4. PubMed ID: 18033786
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Evaluation of in vitro activity of ofloxacin against 73 strains of Chlamydia trachomatis isolated from gynecologic infections].
    Catalan F; Milovanovic A; Prouteau C; Soulignac M
    Pathol Biol (Paris); 1998 Feb; 46(2):144-6. PubMed ID: 9769927
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of the in vitro susceptibility of clinical isolates of chlamydia trachomatis with serovar and duration of antibiotic exposure.
    Zheng H; Xue Y; Bai S; Qin X; Lu P; Yang B
    Sex Transm Dis; 2015 Mar; 42(3):115-9. PubMed ID: 25668641
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Growth cycle-dependent pharmacodynamics of antichlamydial drugs.
    Siewert K; Rupp J; Klinger M; Solbach W; Gieffers J
    Antimicrob Agents Chemother; 2005 May; 49(5):1852-6. PubMed ID: 15855506
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activity of rifaximin and rifampicin against some anaerobic bacteria.
    Lamanna A; Orsi A
    Chemioterapia; 1984 Dec; 3(6):365-7. PubMed ID: 6529778
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New long-acting 3-azinomethyl-rifamycins.
    Bruzzese T; Cedro A; Dell'Acqua E; Di Nardo A; Goi A
    Farmaco Sci; 1986 Mar; 41(3):196-204. PubMed ID: 3709786
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficile.
    Farrell DJ; Putnam SD; Biedenbach DJ; Moro L; Bozzella R; Celasco G; Jones RN
    Antimicrob Agents Chemother; 2011 Mar; 55(3):992-6. PubMed ID: 21149623
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lateral gene transfer in vitro in the intracellular pathogen Chlamydia trachomatis.
    Demars R; Weinfurter J; Guex E; Lin J; Potucek Y
    J Bacteriol; 2007 Feb; 189(3):991-1003. PubMed ID: 17122345
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin.
    Woodley CL; Kilburn JO
    Am Rev Respir Dis; 1982 Sep; 126(3):586-7. PubMed ID: 6289711
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparison of the in-vitro activity of antimicrobials against Chlamydia trachomatis examined by Giemsa and a fluorescent antibody stain.
    How SJ; Hobson D; Hart CA; Quayle E
    J Antimicrob Chemother; 1985 Apr; 15(4):399-404. PubMed ID: 3891709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.